About CHEMI Peptides

Chemi Peptides is a dedicated unit of Chemi SpA, which has a long-term expertise in the development and production of pharmaceutical  peptides from R&D to commercial scale.

Since 1996 Chemi Peptides has been advancing its know-how in Peptides technology and manufacturing, leveraging a team of peptide chemistry experts within Italfarmaco.

Initially involved in the industrial GMP production of peptidic advanced intermediates on a custom manufacturing base, Chemi later focused mainly on both natural and modified API peptides (generics, complex generics, and proprietary peptides).

Peptides

KEY POINTS

Synthesis of Complex or Modified short peptides (max 15-20 AAs or AADs, also unnatural)

Convergent & Minimal protection strategy, for more sustainable processes (low PMI manufacturing)

Management of coupling reactions with control of racemization, for a high stereogenic quality of the final API

Development and validation of complex methods for IPC, release and peptide characterization

GMP manufacturing, featured by isolation and quality characterization of the intermediates

Proprietary know-how in synthetic methods (i.e. non oxidative mono and multi disulfide bridges formation)

Custom Development Capabilities (e.g. challenging cyclization, aminoacid modification, cluster of basic peptides)

GMP manufacturing, featured by isolation and quality characterization of the intermediates

TAG Assisted Peptide Synthesis (TAPS): as part of our ongoing innovation process, we are evaluating and implementing TAPS technology, tailoring it to our expertise.

LPPS plus HPDC: advantages for the customer

HIGHLIGHTS

OUTPUT

Process Development icon
Early development of synthetic and purification process and definition of the impurity profile
Critical impurities already detected at the beginning of the process development
Process Implementation icon
Easy implementation of the process through the different development phases
No change of the impurity profile: evaluation with the customer of potential decreasing
Process Flexibility icon
Flexibility in unexpected production scale changes
Adequate answer to the change of dosage, formulation, sales and marketing evaluation of the customer, etc.
Environmental Safety icon
Environmental contamination reduction
LPPS & Minimal protection strategy + HPDC are the right answer

Manufacturing Expertise - Synthetic strategy

Chemi Peptides is extensively experienced on Industrial Solution Phase Peptide Synthesis (LPPS), both stepwise and by fragments condensation.


Added values:

  • Early development of synthetic (and purification) process, no limits for process scale-up

  • Stable Impurities profile, from the development to the commercial batches

  • Best choice for short/medium and modified peptides

Manufacturing, Purification and Isolation

MANUFACTURING
PURIFICATION AND
ISOLATION
  1. Multi-step chemical synthesis

    Manufacturing
  2. Crude Synthesis

    (stepwise and/or by fragment condensation)

    Manufacturing
  3. Downstream process

    Purification & Isolation
  4. From the crude purification to the final API release

    Purification & Isolation

Purification & Isolation (Down stream process)

The downstream process (purification of the crude peptide and isolation of the final API) is the common bottleneck for all manufacturing strategies.

Chemi Peptides owns an original know-how for reversed phase peptides purification: the High-Performance Displacement Chromatography (HPDC).

This technique allows for an extremely effective purification while lowers the consumption of stationary phase and solvents, ensuring the sustainability of the process.

High Performance Displacement Chromatography (HPDC)

Purification of the crude peptide by reversed phase chromatography

Ion Exchange Chromatography (IEC)

Right counter-ion introduction and removal of impurities with different charge

Reverse Osmosis

Process for removal of the salts and concentration

Ultrafiltration

Deiprogenation

Freeze-drying

Packaging

HPDC advantages

Aqueous-based technique (10-15% solvents max), greener than traditional methods

High loading (e.g. up to 0.4 kg for each run in 25 cm ID column)

A more sustainable process, due to a lower consumption of stationary phase and solvents

High peptide concentration in the fractions (typical 15-25 g/l)

Identification of the critical impurities since the first stages of the development (because of the high concentration/enrichment of the impurities in defined fractions)

Easy scale-up and reproducibility from Lab-scale (0.46 cm ID column) to commercial scale (60 cm ID column factor scale-up = 21096)

Typical chromatographic yield: 80-90% calculated on peptide content

How the HPDC works

Peptides

Peptides developed at R&D scale:

PRODUCT INDICATION API CERTIFICATION ADDITIONAL INFORMATION
Lanreotide Acetate
  • Long-term acromegaly treatment
  • Local advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Pilot level
Scale-up to be planned (Cinisello)
100 g scale
Icatibant Acetate
  • Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children from 2 years old.
Pilot level
Scale-up to be planned (Cinisello)
100 g scale
Linaclotide Acetate
  • Chronic idiopathic constipation
  • IBS with constipation
  • Opioid-induced constipation.
- 50 g scale
Patent US 2025/0042948 A1